Shijiazhuang Yiling Pharmaceutical (002603.SZ): The clinical trial application for the innovative chemical drug "LB220-D08 Sustained-release Tablets" has been accepted.

Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that it has recently received the "Acceptance Notification" issued by the National Medical Products Administration, for a drug named LB220-D08 Sustained-release Tablets. LB220-D08 is a novel small molecule chemical drug independently developed by the company, classified as a Category 1 new chemical drug with independent intellectual property rights. This product is a complement inhibitor targeted at Factor B. By selectively inhibiting the alternative pathway through targeting Factor B, this product can prevent the activation of C3 convertase, thereby inhibiting the generation of toxins such as C3a and C5a, as well as the formation of C5 convertase and the membrane attack complex (MAC, C5b-9), while maintaining the normal function of the lectin and classical pathway signaling pathways.